Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis (ALD518-003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00867516
Recruitment Status : Completed
First Posted : March 23, 2009
Last Update Posted : September 15, 2017
Information provided by (Responsible Party):
Vitaeris INC

Brief Summary:
The purpose of this study is to determine the safety and efficacy of ALD518 in three different doses in patients who have not had an adequate response to methotrexate.

Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Biological: ALD518 Biological: Infusion without ALD518` Phase 2

Detailed Description:

This will be a phase II, parallel-group, double-blind, randomized, placebo-controlled study of ALD518 in patients with active RA with an inadequate response to methotrexate.

Enrolled patients will be screened within a 4-week period (Day -35 to -7). within a 12-day period (Day-14 to -3) before initial dosing on Day 1 patients will be randomized to one of the following four treatment groups:

Group A: 2x ALD518 80 mg Group B: 2x ALD518 160 mg Group C: 2x ALD518 320 mg Group D: 2x placebo

In all treatment groups patients will continue to take a stable dose of methotrexate.

There will be a total of 11 visits. The total duration of the patient study participation will be approximately 16 weeks (excluding the screening period).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 127 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80,160 and 320mg ALD518 Versus Placebo Administered as Multiple IV Infusions to Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Study Start Date : October 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
ALD518 80 mg
Biological: ALD518
Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8

Experimental: 2
ALD518 160 mg
Biological: ALD518
Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8

Experimental: 3
ALD518 320 mg
Biological: ALD518
Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8

Placebo Comparator: 4
No ALD518
Biological: Infusion without ALD518`
250 cc Normal saline IV over one hour Weeks 1 and 8.

Primary Outcome Measures :
  1. Incidence and severity of AEs and SAEs during the study [ Time Frame: During entire length of study ]

Secondary Outcome Measures :
  1. To evaluate the difference in treatment with ALD518 relative to treatment with placebo in the proportion of patients achieving a 20% improvement in ACR response (ACR20) at Week 12 [ Time Frame: 12 weeks after Dose 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Active Rheumatoid Arthritis for at least 16 weeks duration
  • Have a C-reactive protein (CRP) of ≥ 10mg/L
  • Have a stable dose of methotrexate (≥ 10mg/week) for at least 3 months

Exclusion Criteria:

  • Arthritis onset prior to 16 years old
  • Received any biologic therapy in the previous 12 months
  • A history of or currently have active tuberculosis
  • Any clinically significant concurrent medical condition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00867516

Canada, Ontario
K-W Musculoskeletal Research, Inc.
Kitchener, Ontario, Canada, N2M 5N6
Rheumatology Research Associates
Ottawa, Ontario, Canada, KIH IA2
V. Tsitlanadze Scientific Practical Centre of Rheumatology
Tbilisi, Georgia, 0102
Medulla Chemotherapy and Immunotherapy Clinic
Tbilisi, Georgia, 0186
Chanre Rheumatology and Immunology Center and Research
Malleshwaram, Bangalore, India, 560 003
KLE Society Hospital and Medical Research Centre
Nehru Nagar, Belgaum, India, 590 010
Sushrut Hospital, Research Centre & Post Graduate Institute of Orthopaedics
Ramadaspeth, Nagpur, India, 440 010
St. John's Medical College Hospital
Bangalore, India, 560 034
Krishna Institute of Medical Sciences Ltd.
Secunderabad, India, 500 003
Miriada Center Private Clinic of Professor Sierakowski
Bialystok, Poland, 15-297
Nonpublic Centre of Medical Care Reumed
Lublin, Poland, 26-607
NOVAMED - Medical Center of Poznan
Poznan, Poland, 60-773
Provincional Rheumatological Complex named after Dr Jadwiga Titz-Kosko
Sopot, Poland, 81-759
Szezecin Clinic of Rheumatology and Internal Diseases
Szczecin, Poland, 71-252
Russian Federation
Regional Clinical Hospital of War Veterans
Kemerovo, Russian Federation, 650099
Institute of Clinical and Experimental Lymphology
Novosibirsk, Russian Federation, 630117
Ryazan Regional Clinical Cardiologic Dispensary
Ryazan, Russian Federation, 390026
City Hospital #26
Saint Petersburg, Russian Federation, 196247
Saint Petersburg Medical Academy of Postgraduate Study
Saint-Petersburg, Russian Federation, 191015
Saint-Petersburg State Medical Academy named after I. I. Mechnikov
Saint-Petersburg, Russian Federation, 195067
Regional War Veterans' Hospital
Saratov, Russian Federation, 410002
Tomsk Regional Clinical Hospital
Tomsk, Russian Federation, 634063
Tula Regional Clinical Hospital
Tula, Russian Federation, 300053
Clinical Hospital of Emergency Care named after N.V. Solovyev
Yaroslavl, Russian Federation, 150003
Institute of Rheumatology
Belgrade, Serbia, 11000
Institute for Rehabilitation and Treatment Niska Banja
Niska Banja, Serbia, 18205
Sponsors and Collaborators
Vitaeris INC
Study Director: Jeffrey Smith, MD, FRCP Alder BioPharmaceuticals

Responsible Party: Vitaeris INC Identifier: NCT00867516     History of Changes
Other Study ID Numbers: ALD518-CLIN-003
First Posted: March 23, 2009    Key Record Dates
Last Update Posted: September 15, 2017
Last Verified: September 2017

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases